Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has been issued a trademark for RECCE® from the Trade Marks Registry Intellectual Property Department in Hong Kong.
This newly registered trademark in Hong Kong strengthens the company’s intellectual property portfolio with those already registered in the biggest pharmaceutical markets in the world such as USA, Europe, Japan and China as well as in Australia.
Classification
Recce has been issued Class 5 Hong Kong Trademark No. 306020153 and has been classified under the following specification:
- Antibiotics;
- Antibiotics for human use; and
- Pharmaceutical preparations, namely mixed antibiotic preparations.
Hong Kong market
The pharmaceutical market in Hong Kong is valued at US$2.3 billion, with rising demand for chronic disease treatment.
Data presented by the hospital authority of Hong Kong shows a proportionally high level of anti-microbial resistance in both Gram-positive and Gram-negative bacteria, such as Methicillin-resistant Staphylococcus aureus (MRSA), Cephalosporin-resistant and Fluoroquinolone-resistant Escherichia coli, in Hong Kong relative to other countries.
Recce CEO James Graham said: “With Patents in Hong Kong for RECCE® anti-infectives in place out to 2037, we now celebrate further exclusivity through the Trademark registration of RECCE.
Anti-infective pipeline
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives.
RECCE® 327 is an intravenous and topical therapy being developed for the treatment of serious and potentially life-threatening infections due to gram-positive and gram-negative bacteria including their superbug forms.
Meanwhile, RECCE® 435 is an orally administered therapy for bacterial infections; and RECCE® 529 is for viral infections.
Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.